In 2022, monkeypox infections began to spread globally and was declared a United States public health emergency. There is an urgent need for identification of prophylactic and therapeutic approaches for prevention and treatment of monkeypox infection. The goal of this contract is to extend the validation and identification of antibody functions for monkeypox virus (MPXV) A six antibody cocktail, previously identified by the Contractor under this contract program, has shown promise for prevention and treatment of monkeypox in small animal models. However, the inclusion of six antibodies introduces significant manufacturing and regulatory challenges and there is a need to demonstrate functional utility of each antibody in prevention/therapy for MPXV infection.